Previous 10 | Next 10 |
Finding Growth In A No-Growth Market With the second quarter earnings cycle underway the question arises, what sectors should dividend growth investors be targeting? Growth in the second quarter is expected to be negative, estimates for future quarters has fallen and there is a risk the ear...
The following slide deck was published by Meridian Bioscience, Inc. in conjunction with this Read more ...
CINCINNATI, June 03, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has completed its previously announced acquisition of the business of GenePOC Inc., a Quebec City, Quebec, Ca...
Meridian Bioscience Inc. (VIVO) Q2 2019 Earnings and Strategic Acquisition Conference Call April 30, 2019, 10:00 AM ET Company Participants Eric Rasmussen – Chief Financial Officer Jack Kenny – Chief Executive Officer Conference Call Participants Andrew Brackman...
Gainers: Impinj (NASDAQ: PI ) +26% . The Lovesac (NASDAQ: LOVE ) +23% . G1 Therapeutics (NASDAQ: GTHX ) +22% . Oxbridge Re Holdings (NASDAQ: OXBR ) +15% . Sanmina Corporation (NASDAQ: SANM ) +15% . Gaia (NASDAQ: GAIA ) +15% . WageWorks (NYSE: WAGE ) +15% . Brooks Automation (N...
Meridian Bioscience ( VIVO -14% ) suspends quarterly cash dividend in connection with the announcement of the Company’s agreement to acquire the business of GenePOC Inc. and decision to allocate capital to related and other growth initiatives. Previously: Meridian Bio...
The following slide deck was published by Meridian Bioscience, Inc. in conjunction with their 2019 Q2 earnings Read more ...
Meridian Bioscience ( VIVO -11.9% ) Q2 results : Revenues: $50.2M (-11.2%). More news on: Meridian Bioscience, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
CINCINNATI, April 30, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter and first six months ended March 31, 2019. Second Quarter 2019 Highlights: Total revenue decreased 11% to $50.2 million, as compared to $5...
CINCINNATI, April 30, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has entered into a definitive agreement to acquire the business of GenePOC Inc., a Quebec City, Quebec, Cana...
News, Short Squeeze, Breakout and More Instantly...
Meridian Bioscience Inc. Company Name:
VIVO Stock Symbol:
NASDAQ Market:
Meridian Bioscience Inc. Website:
Net revenue for Q4 2022 was $7.1 million, a 15% increase from prior quarter. Net revenue for 2022 was $25.4 million, a 2% increase compared to 2021. Net losses have decreased by 21.2 million in 2022, a 30% decrease from the prior year. The Company signed a definitive agreemen...
Toronto, Ontario--(Newsfile Corp. - March 24, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that it has obtained a final court order (the " Final Order ") from the Ontario Superior Court of Justice (Commercial List) approving the previously announced pl...
Toronto, Ontario--(Newsfile Corp. - March 21, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that, at the special meeting of the shareholders of VIVO (the " Shareholders ") held today (the " Meeting "), the Shareholders approved (i) a special resolutio...